amisulpride

Amisulpride (DAN 2163) (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.

(S)-Amisulpride ((S) Amisulpride) (Esamisulpride) is a potent dopamine D2/D3 receptor antagonist. (S)-Amisulpride is an antagonist at the 5-HT7 receptor with a Ki of 900 nM. (S)-Amisulpride has antipsychotic and antidepressant effects.

N-Methyl amisulpride (Amisulpride impurity H) is a 5-HT7 receptor, D2 receptor, and D3 receptor antagonist used in the study of acute schizophrenia.

Amisulpride-D5 isulpride-D5 is a deuterated compound of Amisulpride. Amisulpride (T0811) has a CAS number of 71675-85-9. Amisulpride  (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.

Amisulpride-D5 (Standard) is a reference standard of Amisulpride-D5 intended for quantitative analysis, quality control, and related biochemical research applications. Amisulpride-d5 is a deuterated compound of Amisulpride. Amisulpride has a CAS number of 71675-85-9. Amisulpride (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.

Amisulpride is an antagonist of 5-HT7 receptor and dopamine D2 and D3 receptors. It modulates beta 2- arresting signaling and increases neurite outgrowth.

Aramisulpride (hydrochloride) is a 5-HT7 receptor antagonist with a Ki value of 22 nM. It also acts as a D2/D3 receptor antagonist, exhibiting a Ki value of 140 nM for D2 receptors and 13.9 nM for D3 receptors. This compound is utilized in the study of psychiatric disorders.

Aramisulpride is a dual antagonist of the dopamine D2 receptor and serotonin receptor, primarily utilized for investigating metabolic disorders.

Amisulpride (Standard) is a reference standard for research and analysis in studies involving Amisulpride. Amisulpride (DAN 2163) (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.